Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.
Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.
复制标题
鼠曲霉菌病的联合抗真菌治疗：脂质体两性霉素 B 和米卡芬净。
DOI：
10.1093/jac/dkg425
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
L. Najvar
中科院分区：
文献类型：
--
作者：
J. Graybill;R. Bocanegra;G. González;L. Najvar
目标
AmBisome和米卡芬净在一系列研究中单独使用和联合使用，旨在确定联合抗真菌治疗的任何累加或拮抗作用。
方法
免疫抑制小鼠通过静脉或鼻内感染烟曲霉菌。米卡芬净、脂质体阿替霉素B或两种药物一起给药7天。有效性参数包括存活率和A的组织负荷。烟熏。
结果
虽然每种药物对小鼠曲霉菌病有效，但仅在有限的实验条件下观察到组织负荷减少的累加效应。未观察到拮抗作用。
结论
目前的研究既不鼓励也不反对联合治疗的临床使用。建议在常规采用联合治疗前进行临床试验。
OBJECTIVES
AmBisome and micafungin were used alone and in combination in a series of studies designed to identify any additive or antagonistic effects of combination antifungal therapy.
METHODS
Immune-suppressed mice were infected either intravenously or intranasally with Aspergillus fumigatus. Micafungin, liposomal amphotericin B or both drugs together were administered for 7 days. Parameters of efficacy included survival and tissue burden of A. fumigatus.
RESULTS
Whilst each drug was effective in murine aspergillosis, additive effects were observed only in reduction of tissue burden in limited experimental conditions. No antagonism was seen.
CONCLUSIONS
The present studies neither encourage nor discourage clinical use of combination therapy. Clinical trials are suggested before combined therapy is routinely adopted.